Navigation Links
Cancer Research UK Offers New Hope To Cancer Patients

In a new clinical development partnership being launched by the Cancer Research UK, and its commercial arm, Cancer Research Technology (CRT) plans to take up// drug candidates that pharmaceuticals companies have ‘deprioritised’ for not showing enough commercial promise following their preclinical studies. By this they plan to develop new treatments from anti-cancer drugs that have been shelved by pharmaceutical and biotechnology companies.

Under the scheme, companies will hand over molecules that once showed promise, but were never developed, and CRT will take on the clinical trials for those molecules. It is proposed that the Pharma and biotech firms will keep the intellectual property rights to the molecules they had shelved. After CRT has done clinical trials, the company will be given the option to take the molecule back and develop it themselves, or to leave it in the hands of the CRT scientists.

Harpal Kumar CRT chief executive hopes that the scheme that would cost up to £2 million a year, will help to identify at least five more drug molecules annually, to add to CRT’s current portfolio of around 25 licensed molecules in the clinic.Kumar sounding very optimistic said that they Hopefully would be flooded with opportunities, he told reporters. Kumar was also keen to state a point that the project was not being developed as a money-spinner for the charity, but he said that the Cancer Research UK does expects to receive a share of any financial return made by the companies.

Richard Tiner, medical director of the Association of the British Pharmaceutical Industry (ABPI) said that he personally could saw no reason for the scheme to fail, but accepted that there could be legal hurdles surrounding intellectual property rights and contracts. He explained that inevitably when discussing business or IP issues there will be differences of opinion. The CRT has approached around 20 leading pharmaceutical and biotech companies, and is c lose to deals with three. Victoria John, head of licensing for the clinical development partnerships scheme, said that those three opportunities is very good at this stage.

Kumar explained that the nature of the scheme means that many of the drug candidates might be used for rare cancers, but this will not colour the decision about which drugs to develop. He explained that just because one type of cancer is common, it doesn’t mean it would get a higher priority than a rarer cancer.

ABPI’s Tiner predicts that other medical charities will be watching the process carefully.

'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Jefferson County, is announcing the launch ... Shelter in Birmingham. , The number of homeless women and children in Birmingham ...
(Date:12/8/2016)... Bay St. Louis, MS (PRWEB) , ... December 08, 2016 , ... ... with offices that serve commercial and residential clients in and around the Hancock County ... community support for the Hancock County Food Pantry. , The Hancock County Food Pantry ...
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Augmedix, the nation,s leading smartglass-based ... closed a $23 million strategic round of funding ... company seeks to rehumanize the physician patient relationship ... EHR documentation. The Augmedix core offering is a ... from 3 hours of mandated charting and documentation ...
(Date:12/8/2016)... N.Y. , Dec. 8, 2016 Henry Schein, ... of health care products and services to office-based dental, animal ... 80 percent equity investment in Marrodent, one of ... of approximately $32 million. This transaction was announced on August ... customers in Poland since 2014, and ...
(Date:12/8/2016)... , and SAN DIEGO , Dec. ... services and solutions with cutting edge next-generation sequencing and bioinformatics ... biotechnology company; and the Genome Institute of Singapore ... – a new joint venture between Novogene and AITbiotech – ... Biopolis, Singapore .   The ...
Breaking Medicine Technology: